Novo Nordisk shares fall 20% after CagriSema failure

Novo Nordisk has seen its shares plummet after its experimental obesity drug CagriSema performed worse than the company expected. Patients taking the drug lost an average of 22.7% of their weight, which was below the expected 25%. This result led to a drastic drop in the market value of the company, which lost approximately $125 billion.

CagriSema is a combination of semaglutide, the active ingredient in Weg's drug, and cagrilintide, which mimics the hormone amylin in the pancreas. The drug was intended to be a stronger competitor to other obesity drugs such as Eli Lilly's Zepbound. While CagriSema achieved significant weight loss, it fell short of the company's stated goal. This result led to a 20% drop in Novo Nordisk's $NVOstock , resulting in a loss of $125 billion in market value for the company. This development raised concerns about the company's ability to develop a successful successor to Wegova, its most successful weight loss drug to date.

Competition and future prospects

Following the release of these results, investor attention has shifted to competitors such as Zepbound, which has shown an average weight loss of around 23% in studies. Nevertheless, some analysts believe that CagriSema still has commercial potential. Although the results have come in below expectations, it is still one of the most effective drugs on the market for obesity. Novo Nordisk plans to file for approval of the drug in 2025 and expects to continue further studies to explore its full potential.

Analyst reaction

Some analysts consider the stock's decline to be overdone. In their view, CagriSema is still the most promising drug on the market, performing better than other available options. Although the company faces strong competition, it still has a chance to succeed if it can optimize the drug's efficacy and better respond to patient tolerance in further clinical trials.

The results of the clinical trials with CagriSema have therefore elicited mixed reactions, but some analysts say the drug could be commercially viable despite initial disappointments. Novo Nordisk still has significant steps to take to regain the confidence of investors and the market.

Disclaimer: There is a lot of inspiration to be found on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source.